Setup

Intellia Therapeutics (NTLA) is an in vivo CRISPR/Cas9 gene editing company. Lead asset lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) hit Phase 3 HAELO on April 27, 2026 — 87% attack reduction vs placebo (p<0.0001), zero SAEs, no Grade ≥3 TEAEs, no hepatotoxicity. Rolling BLA initiated same day. Q1 2026 10-Q filed May 11 hardens commercial commitment and reveals burn trajectory. Short interest 39.3%, idiosyncratic variance 94.7%.

What the filing says

Runway extended to 2028. $194.6M underwritten offering closed April 30 at $10.75/share. Combined with $517M Q1 liquid assets, pro forma cash ≈$711M. Management states "at least into 2028." Prior worldview estimate was H2 2027. Existential overhang on the BLA timeline is removed.

H1 2027 US lonvo-z launch is now in a primary SEC document — Note 1 and MD&A: "preparations are underway for the planned commercial launch of lonvo-z in the first half of 2027" and "expect to complete our BLA submission to the FDA in the second half of 2026 to support a potential U.S. launch." Previously stated only in transcripts and 8-K press releases.

REGN technology collaboration ended April 2026 without new target selection. Note 7: $0.6M deferred revenue remaining "through April 2026, the remaining period of the collaboration." The 2016 Regeneron Agreement target-right lapsed silently. ATTR Co/Co (nex-z, 25% cost share) and Hemophilia A Co/Co survive. ≈$5M/quarter revenue headwind from Q2 2026; REGN one-time optionality on new NTLA targets is gone.

Q1 burn $117.3M operating cash. G&A +20% YoY to $34.8M, explicitly driven by "buildout of the commercial function." R&D -26% YoY. Net loss $96.2M. Annualizing Q1 = ≈$469M; management guides full year lower as R&D decreases.

ATM facility expanded from $750M to $1.04B total in March; $368.5M remaining. 20.1% share dilution Dec 31 → Apr 30. Section 382 NOL limitation risk newly added as a starred risk factor ($1.67B federal NOLs at risk if ownership change triggers).

MAGNITUDE Phase 3 (ATTR-CM and ATTRv-PN): Hold lifted March 2. Q1 10-Q says "patient screening activities are advancing" — not "re-dosing has resumed." The 650+ previously enrolled MAGNITUDE-CM patients face new FDA exclusions (LVEF <25%, recent CV instability).

Tech Square 12-year lease ($189.1M total, ≈$54M/yr by 2031, rent commences Dec 2026) is uncommenced and off-balance-sheet.

What the market thinks

Analyst targets dispersion: Goldman Sell $9, Wedbush Neutral $12, Bernstein Market Perform $17, HC Wainwright Buy $25, Citizens Outperform $30, Canaccord Buy $49-58. Range factor 12x. Mean $26.65, median $22. This is a barbell distribution, not a consensus.

Binary decomposition: at current prices, with "full success" implying ≈$30+ and "failure" implying ≈$5, market implies ≈36% probability of commercial success.

Options: P/C 0.22. ATM IV 78% at 23rd percentile vs 52-wk range (46-184%) — relatively cheap optionality.

Stock fell -8.33% on HAELO day. 39.3% short interest, 6.8 days to cover.

Why the gap exists

Structural analyst coverage gap. Only one analyst (Maury Raycroft, Jefferies) cross-covers NTLA and HAE incumbents. On BCRX Q1 2026 call (May 6), he asked only about Netherton, not ORLADEYO/lonvo-z. HAE specialists (Abrahams, Ku) don't cover NTLA; NTLA analysts don't cover HAE incumbents. The bridging conversation isn't happening structurally.

Incumbent silence extends to SEC filings. KALV 10-Q filed May 14 (17 days post-HAELO) chose not to refresh competitive risk language around gene editing. BCRX 8-K and PHVS 6-K post-HAELO also silent. Incumbents legally required to disclose material competition — choosing not to update — is the inverted-disruptor signal at the strongest disclosure tier.

Sectoral, not HAE-specific. Same dynamic in ATTR-CM cohort: ALNY Q1 call brags 90%+ first-line access, frames forward competition as tafamidis genericization, zero mention of nex-z. BBIO Q1 cites $4B peak ATTRUBY, "competition is Pfizer" — silent on in vivo gene editing. nex-z appears in mandatory 10-Q competitive sections, absent from voluntary management narrative.

REGN strategic posture is ambiguous. Across four consecutive REGN earnings transcripts (Q2 2025 → Q1 2026): zero mentions of CRISPR/gene editing/Intellia/in vivo. Q1 2026 BD signed Telix radiopharma + TriNetX RWD; zero gene editing. Top-3 pharma BD with hands-on CRISPR experience walked from the NTLA target right without disclosed replacement. Bearish read: ecosystem partnership demand softening. Offsetting read: NTLA now retains 100% economics on nex-z.

Risks (ranked by impact)

1. BLA refusal-to-file (≈10-15%) — kills lonvo-z thesis cluster
2. Second LNP-CRISPR hepatic event in MAGNITUDE re-enrollment (≈15%) — platform breaks; read-through to BEAM, CRSP, LLY (VERV)
3. REMS with prescribing restrictions (≈15-20%) — compresses uptake
4. CMC manufacturing scale-up failure for personalized LNP-CRISPR — open gap; binding constraint on H1 2027 timing not disclosed in Q1 10-Q
5. Section 382 NOL limitation triggered — $1.67B federal NOLs at risk
6. Tech Square fixed cost ≈$54M/yr from late 2026 if launch slips
7. HAE incumbent breaks silence with credible counter-narrative
8. Gonzalez securities class action — MTD pending post-Jan 2026 hearing

Catalysts and decision points

What would change our mind

• BLA refusal-to-file, or BLA submission slipping past Q1 2027
• Second clinical hold on any LNP-CRISPR program in next 12 months
• MAGNITUDE-CM enrollment reset (650+ previously enrolled patients requiring full re-screening with material attrition) — slips nex-z timeline 12-18 months
• HAE incumbent presents credible counter-narrative (e.g., BCRX presents durable ORLADEYO retention data)
• REMS draft language indicating significant prescribing restrictions during BLA review
• Stock break below $9.50 on no news — doorway closing toward failure scenario

Evidence